|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 7 (October 1), 1999:
pp. 2200-2207
BCR/ABL mRNA and the P210BCR/ABL Protein Are
Downmodulated by Interferon- in Chronic Myeloid Leukemia
Patients
Fabrizio Pane,
Ilaria Mostarda,
Carmine Selleri,
Rossella Salzano,
Anna Maria Raiola,
Luigia Luciano,
Giuseppe Saglio,
Bruno Rotoli, and
Francesco Salvatore
From the CEINGE-Biotecnologie Avanzate, Dipartimento di Biochimica e
Biotecnologie Mediche and Divisione di Ematologia, Facoltá di
Medicina, Universitá Federico II, Naples; Dipartimento di Scienze
Biomediche e Oncologia Umana, Universitá di Torino, Italy.
The BCR/ABL hybrid gene plays a central role in the pathogenesis of
the chronic phase of chronic myeloid leukemia (CML). We used a very
sensitive quantitative reverse transcriptase-polymerase chain
reaction to investigate the levels of hybrid BCR/ABL mRNA in bone
marrow cells of 20 patients with Philadelphia positive (Ph+) CML treated with interferon- (IFN-) as a
single agent. Bone marrow samples were collected at diagnosis and at
hematologic remission induced by IFN-, or by hydroxyurea in case of
resistance to IFN-. The mean levels of BCR/ABL transcripts in bone
marrow mononuclear cells of patients who showed a complete hematologic response to IFN- were significantly reduced with respect to those at
diagnosis (48 × 103 v
168 × 103; P < .001), whereas no difference
was detected between the values at diagnosis and at hematologic
remission in patients resistant to IFN-. In cell culture
experiments, IFN- priming significantly reduced the levels of
BCR/ABL hybrid transcripts in a dose-dependent manner in Ph+ bone
marrow precursors obtained at diagnosis from patients who subsequently
responded to IFN- treatment (P < .005). No
downmodulation was observed in bone marrow precursors from patients who
subsequently proved to be IFN-resistant. These results indicate that
downmodulation of BCR/ABL gene expression could be one of the
mechanisms involved in the response of CML patients to IFN- treatment.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Jin, Y. Tabe, S. Konoplev, Y. Xu, C. E. Leysath, H. Lu, S. Kimura, A. Ohsaka, M.-B. Rios, L. Calvert, et al.
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Mol. Cancer Ther.,
January 1, 2008;
7(1):
48 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Selleri, J. P. Maciejewski, N. Montuori, P. Ricci, V. Visconte, B. Serio, L. Luciano, and B. Rotoli
Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells
Blood,
August 15, 2003;
102(4):
1490 - 1498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bagg
Chronic Myeloid Leukemia: A Minimalistic View of Post-Therapeutic Monitoring
J. Mol. Diagn.,
February 1, 2002;
4(1):
1 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Deng and G. Q. Daley
Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia
Blood,
June 1, 2001;
97(11):
3491 - 3497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Reuben, B.-N. Lee, H. Johnson, H. Fritsche, H. M. Kantarjian, and M. Talpaz
Restoration of Th1 Cytokine Synthesis by T Cells of Patients with Chronic Myelogenous Leukemia in Cytogenetic and Hematologic Remission with Interferon-{{alpha}}
Clin. Cancer Res.,
May 1, 2000;
6(5):
1671 - 1677.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. Era and O. N. Witte
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate
PNAS,
February 15, 2000;
97(4):
1737 - 1742.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, J. V. Melo, S. Tura, S. Giralt, and M. Talpaz
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies
Hematology,
January 1, 2000;
2000(1):
90 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. A. Mayer, A. Verma, I. M. Grumbach, S. Uddin, F. Lekmine, F. Ravandi, B. Majchrzak, S. Fujita, E. N. Fish, and L. C. Platanias
The p38 MAPK Pathway Mediates the Growth Inhibitory Effects of Interferon-alpha in BCR-ABL-expressing Cells
J. Biol. Chem.,
July 20, 2001;
276(30):
28570 - 28577.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
